Comprehensive genomic profiling service for haematological malignancies and sarcomas; to guide diagnosis, prognosis and treatment selection and personalise patients’ treatment plans.1–3

2.4 Foundationone-heme_v1

Comprehensive assessment in a single test

FoundationOne Heme comprehensively analyses the cancer genome to identify clinically relevant genomic alterations in haematological malignancies and sarcomas.1,2

2.4 Cancer sequencing_v1

Delivers insights in a single test, thus saving time and avoiding repeat biopsy versus sequential biomarker testing.1


Integrated DNA and RNA sequencing helps identify common, rare, and novel gene fusions and rearrangements 1,2

Distribution of rearrangements called by detection method2


Adapted from He et al. 2016.


Supports clinical decision-making

A clear, in-depth report supports your clinical decision-making by providing insights on the genomic profile of your patient as well as associated targeted therapies, immunotherapies and relevant clinical trials. The report also highlights important disease-relevant genes with no reportable alterations identified and genomic alterations associated with potential resistance to therapy, to help rule out ineffective treatment.23

786210280-002_F1 L CDx report services EU cc02-01 (page 40).png

Reports four main classes of alterations spanning the DNA of 406 genes and the RNA of 265 genes in just 3 weeks following receipt of the sample at our laboratory1


Personalises treatment plans in haematological malignancies 

FoundationOne Heme enables guideline-recommended testing to help guide diagnosis, prognosis and treatment selection, with the potential to improve patient outcomes.1,4–17


Using FoundationOne Heme for haematological malignancies


Personalises treatment plans for sarcomas 

FoundationOne Heme helps guide diagnosis, prognosis and treatment selection, with the potential to improve outcomes for sarcoma patients.1,3,18–20


High clinical utility in paediatric patients

  • FoundationOne Heme is for haematological malignancies and sarcomas, which have relatively high incidences among malignancies in the paediatric population18,35
  • FoundationOne Heme integrates DNA and RNA sequencing to identify complex genomic rearrangements, which are characteristic of haematological malignancies and sarcomas in paediatric patients1,13,35–38
2.4 High clinical utility in paediatric patients_v2-01.png

932 AML specimens including 179 paediatric (age 0–18) and 753 adults (age ≥ 19).


Order FoundationOne Heme

Experience how FoundationOne Heme can guide diagnosis, prognosis and treatment selection, and help personalise your patients’ treatment plans.1–3

FoundationOne Heme samples can be shipped to our Penzberg (Germany) or Cambridge (US) laboratories for patients in the EU or the rest of the world, respectively, enabling more patients to benefit from comprehensive genomic profiling with FoundationOne Heme.

 Acceptable specimen types:

  • For haematological malignancies, multiple specimen types are acceptable; FoundationOne Heme has been validated with blood, bone marrow aspirate and FFPE tissue samples1,39
  • For sarcoma, please use FFPE tissue samples39
  • Our dedicated client service team offers information and support to ensure specimen requirements for analysis are met

*Base substitutions, insertions or deletions, copy number alterations and gene rearrangements.

Peripheral blood and bone marrow aspirate must be received the day after collection for optimal analysis as sensitivity of detection may degrade with time. Samples arriving later will result in a Qualified Report. FFPE block or slides are also accepted.

AML, acute myeloid leukaemia. ALL, acute lymphoblastic leukaemia. CLL, chronic lymphocytic leukaemia. GIST, gastrointestinal stromal tumours. DLBCL, diffuse large B-cell lymphoma. FFPE, formalin-fixed paraffin-embedded. MDS, myelodysplastic syndrome. MM, multiple myeloma. MPN, myeloproliferative neoplasms. MSI, microsatellite instability. RMS, rhabdomyosarcoma. TKI, tyrosine kinase inhibitor. TMB, tumour mutational burden.